Invesco Ltd. Exelixis, Inc. Transaction History

Invesco Ltd.

$503 Billion
Q1 2025

A detailed history of Invesco Ltd. transactions in Exelixis, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 5,572,189 shares of EXEL stock, worth $243 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

5,572,189

Previous 3,975,241 40.17%

Holding current value

$243 Million

Previous $132 Million 55.41%

% of portfolio

0.04%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$32.38 - $39.16 $51.7 Million - $62.5 Million	1,596,948 Added 40.17%	5,572,189 $206 Million
Q4 2024 Feb 13, 2025	BUY	$25.39 - $36.46 $76.2 Million - $109 Million	3,001,204 Added 308.12%	3,975,241 $132 Million
Q3 2024 Nov 12, 2024	SELL	$21.96 - $27.6 $3.1 Million - $3.9 Million	-141,152 Reduced 12.66%	974,037 $25.3 Million
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $4.46 Million - $5.2 Million	-219,306 Reduced 16.43%	1,115,189 $25.1 Million
Q1 2024 May 14, 2024	SELL	$20.17 - $23.93 $8.76 Million - $10.4 Million	-434,097 Reduced 24.54%	1,334,495 $31.7 Million
Q4 2023 Feb 12, 2024	BUY	$19.25 - $24.13 $6.31 Million - $7.91 Million	328,010 Added 22.77%	1,768,592 $42.4 Million
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $4.36 Million - $5.21 Million	229,242 Added 18.92%	1,440,582 $31.5 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $2.76 Million - $3.11 Million	-151,994 Reduced 11.15%	1,211,340 $23.1 Million
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $14.8 Million - $17.6 Million	-905,622 Reduced 39.91%	1,363,334 $26.5 Million
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $7.86 Million - $9.13 Million	525,246 Added 30.12%	2,268,956 $36.4 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $8.85 Million - $12.6 Million	564,623 Added 47.89%	1,743,710 $27.3 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $4.6 Million - $6.11 Million	263,642 Added 28.8%	1,179,087 $24.5 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $2.02 Million - $2.69 Million	-118,556 Reduced 11.47%	915,445 $20.8 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $2.89 Million - $3.99 Million	-182,300 Reduced 14.99%	1,034,001 $18.9 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $1.9 Million - $2.46 Million	116,480 Added 10.59%	1,216,301 $25.7 Million
Q2 2021 Aug 17, 2021	BUY	$17.95 - $25.56 $6.28 Million - $8.94 Million	349,925 Added 46.66%	1,099,821 $20 Million
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $4.59 Million - $5.64 Million	-223,768 Reduced 22.98%	749,896 $16.9 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $2.46 Million - $3.32 Million	133,759 Added 15.93%	973,664 $19.5 Million
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $5.6 Million - $7.3 Million	270,897 Added 47.61%	839,905 $20.5 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $6.04 Million - $10.1 Million	-367,138 Reduced 39.22%	569,008 $13.5 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $4.9 Million - $7.39 Million	338,785 Added 56.71%	936,146 $16.1 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $882,623 - $1.1 Million	-58,259 Reduced 8.89%	597,361 $10.5 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $4.22 Million - $5.41 Million	238,634 Added 57.23%	655,620 $11.6 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $10.9 Million - $14.3 Million	-576,683 Reduced 58.04%	416,986 $8.91 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $5.3 Million - $6.69 Million	270,333 Added 37.37%	993,669 $23.6 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $9.87 Million - $15.8 Million	723,336 New	723,336 $14.2 Million

Others Institutions Holding EXEL

# of Institutions

613

Shares Held

257M

Call Options Held

1.57M

Put Options Held

730K

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $14.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account